Get the Stockscreener App
0.78
41.84%
0.2301
Protagenic Therapeutics Inc stock is traded at $0.78, with a volume of 4,369.
It is up +41.84% in the last 24 hours and up +33.33% over the past month.
PROTAGENIC THERAPEUTICS
See More
Previous Close:
$0.5499
Open:
$0.8188
24h Volume:
4,369
Relative Volume:
4.74
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-5.16M
P/E Ratio:
-0.2263
EPS:
-3.4464
Net Cash Flow:
$-4.14M
1W Performance:
+41.84%
1M Performance:
+33.33%
6M Performance:
-82.90%
1Y Performance:
-90.59%
1-Day Range:
$0.53
$0.9007
1-Week Range:
$0.53
$0.9007
52-Week Range:
$0.5003
$0.9007
Protagenic Therapeutics Inc Stock (PTIX) Company Profile
Name
Protagenic Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare PTIX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTIX
Protagenic Therapeutics Inc
|
0.78 | 0 | 0 | -5.16M | -4.14M | -3.4464 |
VRTX
Vertex Pharmaceuticals Inc
|
437.70 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
709.88 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.64 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.56 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
316.56 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagenic Therapeutics Inc Stock (PTIX) Latest News
TradingKey - TradingKey
PTIXW SEC FilingsProtagenic 10-K, 10-Q, 8-K Forms - Stock Titan
Why Is Protagenic Therapeutics, Inc. (PTIX) Stock Up Today? - Meyka
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 - Caledonian Record
Protagenic names Bill Nichols president, CFO to step down By Investing.com - Investing.com Nigeria
Protagenic Therapeutics Names Bill Nichols Jr. President to Advance Neuropeptide Pipeline Strategy - citybiz
Protagenic names Bill Nichols president, CFO to step down - Investing.com
Protagenic adds ex-bluebird executive as PT00114 moves toward Phase 2 - Stock Titan
Bristol-Myers Squibb (BMY) Veteran Bill Nichols Jr. Appointed President of Protagenic Therapeutics to Accelerate First-in-Class TCAP Therapy DevelopmentAI Stock Signals - newser.com
PTIX SEC FilingsProtagenic Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Guidance Update: What is the long term forecast for Protagenic Therapeutics Inc stock2026 Volume Leaders & Trade Opportunity Analysis - baoquankhu1.vn
Sentiment Review: Is Protagenic Therapeutics Inc Equity Warrant showing insider buyingWeekly Gains Summary & Weekly Return Optimization Plans - baoquankhu1.vn
Rate Hike: Is Protagenic Therapeutics Inc being accumulated by smart money2026 Winners & Losers & Safe Entry Zone Tips - baoquankhu1.vn
PTIX | PROTAGENIC THERAPEUTICS Insider Trading - Quiver Quantitative
Analyst Upgrade: How much upside does Protagenic Therapeutics Inc have2026 Technical Overview & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Investor Mood: What is the long term forecast for Protagenic Therapeutics Inc stockDip Buying & Detailed Earnings Play Alerts - baoquankhu1.vn
PTIX|Protagenic Therapeutics Inc|Price:0.740| - TradingKey
Fed Meeting: Will Protagenic Therapeutics Inc Equity Warrant outperform during market rallies2026 Rallies & Low Drawdown Trading Techniques - baoquankhu1.vn
Market Pulse: Does Protagenic Therapeutics Inc have a sustainable dividendMarket Sentiment Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Protagenic Therapeutics Announces Termination of Chief Financial Officer - The Globe and Mail
Trend Review: Whats the beta of Protagenic Therapeutics Inc stock2026 Fundamental Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Protagenic Therapeutics IncAlexander Arrow, CFO, to be terminated effective April 30, 2026SEC filing - marketscreener.com
Protagenic Therapeutics CFO Alexander Arrow to Exit, Termination Effective April 30, 2026 - TradingView — Track All Markets
Protagenic Therapeutics, Inc. Announces Employment Termination of Alexander Arrow as Chief Financial Officer, Effective April 30, 2026 - marketscreener.com
Protagenic Therapeutics (PTIX) CFO Alexander Arrow set to exit role - Stock Titan
ETF Watch: What is the long term forecast for Protagenic Therapeutics Inc stockMarket Sentiment Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
ETF Watch: Is Protagenic Therapeutics Inc Equity Warrant a turnaround story2026 Valuation Update & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
EV Market: Whats the beta of Protagenic Therapeutics Inc stockQuarterly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Aug Summary: What is the long term forecast for Protagenic Therapeutics Inc stockTrade Volume Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Aug Setups: Is Protagenic Therapeutics Inc Equity Warrants growth already priced in2026 Retail Activity & Weekly Top Performers Watchlists - baoquankhu1.vn
US Stocks Recap: Can Protagenic Therapeutics Inc Equity Warrant maintain sales growth2026 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Gainers Report: Whats the profit margin of Protagenic Therapeutics Inc Equity Warrant2026 Key Lessons & Growth Focused Entry Point Reports - baoquankhu1.vn
Volume Summary: Does Protagenic Therapeutics Inc align with a passive investing strategyGlobal Markets & Daily Chart Pattern Signals - baoquankhu1.vn
If You Invested $1,000 in Protagenic Therapeutics Inc (PTIX) - Stock Titan
Options Flow: Is Protagenic Therapeutics Inc being accumulated by smart money2026 Trends & Consistent Profit Trading Strategies - baoquankhu1.vn
Trading Recap: Why is Protagenic Therapeutics Inc stock going downQuarterly Trade Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Protagenic settles Phytanix separation, cuts liabilities by $6.3M - Investing.com
Protagenic Therapeutics (PTIX) Streamlines Operations and Focuses on Key Asset - GuruFocus
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 - guardonline.com
Protagenic slashes $6.3M liabilities to focus on new depression treatment - Stock Titan
Market Pulse: Whats the profit margin of Protagenic Therapeutics Inc Equity WarrantWeekly Profit Recap & Consistent Return Strategy Ideas - baoquankhu1.vn
Protagenic Therapeutics Upgrades to OTCQB Venture Market - National Today
Protagenic Therapeutics (PTIX) Upgrades to OTCQB Market - GuruFocus
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market - ACCESS Newswire
Protagenic biotech gains OTCQB listing as depression drug nears Phase 2 - Stock Titan
Protagenic Therapeutics, Inc. (PTIX) 10-Q Quarterly Report for December 31, 2025 – Financials, Filings, and Nasdaq Listing - Minichart
Protagenic Therapeutics 10-Q: $0 Revenue, $1.14 EPS, operating loss $0.93M - TradingView
Protagenic Therapeutics : Quarterly Report for Quarter Ending December 31, 2025 (Form 10-Q) - marketscreener.com
Protagenic Therapeutics (PTIX) posts derivative-driven profit but warns on going concern - Stock Titan
Protagenic Therapeutics Inc Stock (PTIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.25%
3.16%
Cap:
|
Volume (24h):